Can a modified herpes virus turn the tide against advanced cancer?

NCT ID NCT04386967

First seen Aug 06, 2026 · Last updated Aug 07, 2026 · Updated 1 time

Summary

This early-stage trial is testing an investigational therapy called OH2, a modified herpes simplex virus designed to infect and destroy cancer cells while also stimulating the immune system. The study will evaluate OH2 alone or in combination with the immunotherapy drug pembrolizumab (Keytruda) in people with advanced solid tumors, including melanoma. The main goals are to determine the safety, appropriate dosing, and potential anti-tumor activity of this approach.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
OH2 injection, an engineered herpes simplex virus that targets tumors, with or without pembrolizumab (Keytruda)
What this could lead to
If successful, this could lead to a new treatment option for advanced solid tumors, potentially improving outcomes for patients who have exhausted standard therapies.
What could go wrong
This is an early-phase trial, so the treatment may not be effective or may cause significant side effects. The virus and combination therapy are still experimental.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Peking University Cancer Hospital

    Beijing, Beijing Municipality, 100010, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.